SCHEDULE 13G/A: Farallon Capital Discloses 6.8% Stake in Revolution Medicines, Inc. via Amended SEC Filing

Farallon Capital and its affiliated entities have filed an amended Schedule 13G, disclosing a collective beneficial ownership of 11,331,045 shares, representing approximately 6.8% of Revolution Medicines, Inc.'s common stock, noting a late filing due to administrative error.

Summary

• Farallon Capital Partners, L.P., and its various affiliated funds (collectively, the "Farallon Funds") along with their general partners and individual managing members, have reported beneficial ownership in Revolution Medicines, Inc.
• The aggregate beneficial ownership by the Farallon group amounts to 11,331,045 shares of Revolution Medicines, Inc. Common Stock.
• This ownership represents approximately 6.8% of the total outstanding shares of Revolution Medicines, Inc.
• The reported shares include 11,317,692 directly held shares and 120,085 Common Stock Purchase Warrants, each exercisable for 0.1112 shares, contributing an additional 13,354 shares.
• The filing is an Amendment No. 1 to a previous Schedule 13G and was submitted late due to an inadvertent administrative error.
• The reporting persons explicitly state that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, except for activities solely related to a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or outlook. The late filing is a minor administrative note.

Future Outlook

NA

Industry Context

This filing is a standard disclosure for institutional investors like Farallon Capital, indicating a significant, but passive, ownership stake in a publicly traded biotechnology company. It does not provide specific insights into Revolution Medicines, Inc.'s operational performance or strategic direction, but rather reflects an investment position by a major fund.

Related Party Transactions

• The filing details the complex ownership structure within the Farallon Capital group, where various limited partnerships (Farallon Funds) hold shares, and their general partners and individual managing members are deemed beneficial owners due to their control over these funds. This represents an internal related-party structure for reporting purposes.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake in Revolution Medicines, Inc., confirming a substantial, albeit passive, ownership position by Farallon Capital.

Key Dates

Keywords

Revolution Medicines Inc., Farallon Capital, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Warrants, Biotechnology, Healthcare